Reirradiation in Head and Neck Cancer: A Curative Intent in Recurrence or Second TumorsEnrique Jurado Martín1*, Vladimir Suarezb2, Ismael Herruzo Cabrera3, Lourdes de la Peña3, Gustavo Ossola Lentatia1, Maria José Ortiz Gordillob2 and Jerónimo Pachon Ibañezb2
- *Corresponding Author:
- Enrique Jurado Martín
Radiation Oncology Unit
Rioja Salud Foundation-San Pedro Hospital, La Rioja, Spain
Tel: +63 82 221 4950
E-mail: [email protected]
Received date: January 29, 2016 Accepted date: February 16, 2016 Published date: February 23, 2016
Citation: Martín EJ, Suarezb V, Cabrera IH, Peña LDL, Lentatia GO, et al. (2016) Reirradiation in Head and Neck Cancer: A Curative Intent in Recurrence or Second Tumors. J Nucl Med Radiat Ther 7:281. doi: 10.4172/2155-9619.1000281
Copyright: © 2016 Martín EJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License; which permits unrestricted use; distribution; and reproduction in any medium; provided the original author and source are credited.
Purpose: To assess the efficacy and safety of reirradiation in head and neck cancer and potential prognostic factors associated. Material and methods: Cohort study of patients treated with curative reirradiation for recurrence or second primary tumor. The analysis of RR is obtained prospectively from the database available at both centers. Statistical analysis was performed using the R Commander 2.0 software. Results: Between 2006 and 2013, 40 patients with head and neck carcinoma were reirradiated. The mean dose was 66.39 Gy. 35% of patients showed acute toxicity grade 3 or higher and 20.5% showed chronic toxicity grade 2 or higher. The median follow-up was 11 months. The overall survival at 2 years was 41%; disease free survival and locoregional control at 1 year was 35.9% and 41.1% respectively. The time between treatments and disease-free interval to death and local recurrence were statistically significant (p < 0.05); and the first treatment scheme to distant metastases.